Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model

Ana I. Arroyo, Paola G. Camoletto, Laura Morando, Marco Sassoe-Pognetto, Maurizio Giustetto, Paul P. Van Veldhoven, Edward H. Schuchman, Maria D. Ledesma

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Understanding the role of lipids in synapses and the aberrant molecular mechanisms causing the cognitive deficits that characterize most lipidosis is necessary to develop therapies for these diseases. Here we describe sphingomyelin (SM) as a key modulator of the dendritic spine actin cytoskeleton. We show that increased SM levels in neurons of acid sphingomyelinase knock out mice (ASMko), which mimic Niemann Pick disease type A (NPA), result in reduced spine number and size and low levels of filamentous actin. Mechanistically, SM accumulation decreases the levels of metabotropic glutamate receptors type I (mGluR1/5) at the synaptic membrane impairing membrane attachment and activity of RhoA and its effectors ROCK and ProfilinIIa. Pharmacological enhancement of the neutral sphingomyelinase rescues the aberrant molecular and morphological phenotypes in vitro and in vivo and improves motor and memory deficits in ASMko mice. Altogether, these data demonstrate the influence of SM and its catabolic enzymes in dendritic spine physiology and contribute to our understanding of the cognitive deficits of NPA patients, opening new perspectives for therapeutic interventions.

Original languageEnglish
Pages (from-to)398-413
Number of pages16
JournalEMBO Molecular Medicine
Volume6
Issue number3
DOIs
StatePublished - Mar 2014

Keywords

  • Dexamethasone
  • Niemann Pick
  • RhoA
  • Sphingomyelin

Fingerprint

Dive into the research topics of 'Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model'. Together they form a unique fingerprint.

Cite this